Humane Genomics vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic oncolytic virus biotech engineering programmable cancer-killing RNA viruses; $8.12M raised with Union Square Ventures leading 2025 round competing in cancer immunotherapy.
About
Humane Genomics is a synthetic virology biotech company engineering oncolytic viruses — synthetic RNA viruses designed to selectively infect and destroy cancer cells while leaving healthy cells unharmed — using a proprietary platform that programs viral behavior at the genomic level to create next-generation cancer therapies. The company raised $8.12 million in total funding including a February 2025 round led by Union Square Ventures with 14 investor participants, developing RNA-based viral cancer therapies for systemic delivery designed for extended therapeutic activity.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.